Kupando receives 13 million euros

The start-up was able to convince Remiges Ventures and High-Tech Gründerfonds, among others, in its Series A financing round.

Biopharma start-up Kupando has raised €13 million in its Series A financing round. Venture capitalist Remiges Ventures leads the round. Co-lead investor is Lifecare Partners, with money also coming from Brandenburg Kapital, High-Tech Gründerfonds, Ventura Biomed Investors and several family offices.

Kupando is developing substances to stimulate innate immunity against cancer and other infectious diseases. The start-up says it has a drug candidate, KUP101, for which it now plans to apply for a clinical trial. "It's really nice that we now have the opportunity to develop compounds that can make a difference in the treatment of solid tumors and the prevention of infectious diseases in terms of efficacy, safety and financial affordability," says Johanna Holldack, CEO of Kupando.

The startup also receives praise from its lead investor. "Kupando is a true pioneer in the development of a novel innate immunity stimulator, and we look forward to working with the team and supporting the advancement of KUP101 into clinical development," says Kazuhiko Nonomura of Remiges Ventures.